Home › Therapeutic areas › Oncology › Breast Cancer
Breast Cancer (23 companies)
Companies with an active program in Breast Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | $910M | 10 |
| ANIX | Anixa Biosciences | Oncology | 1 | Phase 1 | $92.8M | 3 |
| ARTV | Artiva Biotherapeutics | Oncology | 1 | Phase 1 | $191M | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $447M | 10 |
| BCTX | BriaCell Therapeutics | Oncology | 3 | Phase 3 | $30.7M | 8 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | $9.2M | 7 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CYDY | CytoDyn | NeurologyOncology | 1 | Phase 2 | $367M | 3 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | $279M | 13 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Preclinical | $110M | 4 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $274M | 1 |
| IDYA | IDEAYA Biosciences | Oncology | 2 | NDA Submitted | $2.65B | 15 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.03B | 9 |
| KAPA | Kairos Pharma | Oncology | 1 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 2 | Phase 2 | $60.7M | 13 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $775M | 7 |
| OLMA | Olema Pharmaceuticals | Oncology | 2 | Phase 3 | $633M | 3 |
| OKUR | OnKure Therapeutics | Oncology | 1 | Preclinical | $104M | 2 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $831M | 5 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 1 | Phase 1 | $266M | 3 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $3.64B | 4 |
No companies match.